Year Founded
2012
Ownership
Private
Employees
~50
Therapeutic Areas
GastroenterologyPulmonologyMetabolic DisordersImmunologyEndocrinologyOncologyInfectious Diseases
Stage
Phase 1
Modalities
Small moleculeProtein therapeuticsAdoptive cell therapyPeptidesPolymer-based drug delivery

Calibr General Information

Multiple programs in clinical development including mocetinostat for osteoarthritis, CBE161/MMV371 for malaria, and CMR316 for idiopathic pulmonary fibrosis. Lead program mocetinostat shows promising results in preclinical osteoarthritis models.

Contact Information

Website
Primary Industry
[ "Biotech", "CRO" ]
Corporate Office

Drug Pipeline

mocetinostat
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Calibr's pipeline data

Book a demo

Key Partnerships

Medicines for Malaria Venture, Bill & Melinda Gates Foundation, Bill & Melinda Gates Medical Research Institute

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Calibr Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Calibr's complete valuation and funding history, request access »

Calibr Investors

Merck & Co. ($90M initial commitment)
Investor Type: Venture Capital
Holding: Minority
philanthropic support including ALSAM Foundation / Skaggs family
Investor Type: Venture Capital
Holding: Minority